| Dr Donald P Peyser, MD | |
|
225 Millburn Ave, Suite 104-a, Millburn, NJ 07041-1737 | |
| (973) 467-5800 | |
| (973) 467-9163 |
| Full Name | Dr Donald P Peyser |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 225 Millburn Ave, Millburn, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336141290 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Donald P Peyser, MD 225 Millburn Ave, Suite 104-a, Millburn, NJ 07041-1737 Ph: (973) 467-5800 | Dr Donald P Peyser, MD 225 Millburn Ave, Suite 104-a, Millburn, NJ 07041-1737 Ph: (973) 467-5800 |
News Archive
International group of scientists in the joint study of the laboratory of the Wistar Institute, University of Pittsburgh and I.M. Sechenov First Moscow State Medical University discovered the change in activity of one of the immune cells types called neutrophils during the cancer development: they begin to prevent other immune cells from fighting tumor and thus decelerate treatment.
Heart attack patients who develop serious arrhythmia in connection with procedures to open blocked arteries face a significantly higher risk of death for several months after the procedure, when compared to similar patients who do not develop such complications, according to new research from Duke University Medical Center.
MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.
Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared to the royalty rate set under the original licensing agreement signed in 2004 for sales in the rest of the world.
› Verified 7 days ago
Dr. Errol Meisner, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 425 Essex St, Millburn, NJ 07041 Phone: 973-467-0866 Fax: 973-467-5485 | |
Manuel Jacobo Mendez Jr., M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 235 Millburn Ave Ste 101, Millburn, NJ 07041 Phone: 973-376-8034 | |
Rajendra Desai, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 116 Millburn Ave, Suite 213, Millburn, NJ 07041 Phone: 973-376-8454 Fax: 973-376-7808 | |
Dr. Danielle Louisa Jardine, M.B,B.S. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 120 Millburn Ave Ste 204, Millburn, NJ 07041 Phone: 973-467-9282 | |
Dr. Yatinder Bains, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 116 Millburn Ave, Suite # 214, Millburn, NJ 07041 Phone: 973-376-2121 Fax: 973-467-0150 | |
Dr. Richard Evan Freundlich, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 225 Millburn Ave, Suite 209, Millburn, NJ 07041 Phone: 973-218-9330 Fax: 973-218-9351 | |
Pratibha Avinash Kulkarni, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 116 Millburn Ave, Suite # 108, Millburn, NJ 07041 Phone: 973-564-5227 |